<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093818</url>
  </required_header>
  <id_info>
    <org_study_id>668353 (U-PGx)</org_study_id>
    <nct_id>NCT03093818</nct_id>
  </id_info>
  <brief_title>PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions</brief_title>
  <acronym>PREPARE</acronym>
  <official_title>PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J.J.Swen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro di Riferimento Oncologico - Aviano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Golden Helix Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Dutch Pharmacists Association (KNMP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bio.Logis Genetic Information Management</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paul Sabatier University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robert Bosch Gesellschaft f√ºr Medizinische Forschung mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Institute for Drugs and Medical Devices</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREPARE is an international, prospective, multi-center, open, randomized, cross-over
      implementation study assessing the impact of pre-emptive pharmacogenomic testing, of a panel
      of actionable pharmacogenomic variants, on adverse event incidence. Additional outcomes
      include, healthcare expenditure, process indicators for implementation and provider adoption
      of pharmacogenomics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-emptive pharmacogenomic testing will be implemented in clinical sites across seven
      European countries (United Kingdom, The Netherlands, Austria, Greece, Slovenia, Italy and
      Spain). The 36-month study is split into two 18-month blocks. The participating countries are
      randomized to start with either implementing pharmacogenomics guided prescribing or with
      standard of care in the first block. In the pharmacogenomics guided prescribing arm, results
      of the pharmacogenomic test will be incorporated in the (electronic) medical record and may
      be used by physicians and pharmacists to guide drug and dose selection for 42 routinely
      prescribed drugs, as per the Dutch Pharmacogenomics Working Group guidelines. In the standard
      of care arm, patients will not receive pharmacogenomic testing. After this 18-month block,
      the countries switch to implementing the opposite strategy and will recruit new patients.

      Patients are eligible for participation when they receive a first prescription for one or
      more of 42 drugs for which a Dutch Pharmacogenomic Working Group guideline is available
      (acenocoumarol, amitriptyline, aripiprazole, atomoxetine, atorvastatin,azathioprine
      ,capecitabine, carbamazepine, citalopram, clomipramine, clopidogrel , clozapine, codeine,
      doxepin, efavirenz, escitalopram, flecainide, flucloxacillin, fluorouracil, haloperidol,
      imipramine, irinotecan, mercaptopurine, metoprolol, nortryptiline, oxycodone, paroxetine,
      phenprocoumon, phenytoin, pimozide, propafenon, sertraline, simvastatin, tacrolimus,
      tamoxifen, tegafur, thioguanine, tramadol, venlafaxine, voriconazole, warfarin or
      zuclopenthixol). All patients will be followed for a minimum of three months and a maximum of
      18 months. In total, 8,100 patients will be recruited; 4,050 will receive pharmacogenomic
      testing, and 4,050 will receive standard of care. Each implementation site will concentrate
      on, but is not limited to, recruiting patients within a specific therapeutic area.
      Therapeutic areas include primary care, general medicine, cardiology, oncology, psychiatry,
      neurology, and transplantation. It is hypothesized that implementing pharmacogenomics guided
      drug and dose selection will decrease incidence of clinically relevant adverse drug reactions
      by 30% (from 4% to 2.8%).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Causality and severity of recorded ADE will be assessed by a 2nd independent, blinded (unaware of patient allocation) assessor.
Drug-genotype association of the ADE as per the Dutch Pharmacogenomics Working Group guideline will be assessed by a blinded review committee.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Experience of at least one clinically relevant adverse drug reaction which is caused by the drug of inclusion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as an adverse drug reaction which is causally related to the drug of inclusion (definite, probable or possible), clinically relevant (CTCAE Grade 2,3,4 or 5) and associated with a drug-genotype interaction (as per the Dutch Pharmacogenomics Working Group guidelines)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician and pharmacist adherence to Dutch Pharmacogenomics Working Group guidelines</measure>
    <time_frame>18 months</time_frame>
    <description>Defined as adhering to the guidelines or not adhering to the guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare expenditure related to adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Any costs made as a result of an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug discontinuation due to an adverse event</measure>
    <time_frame>18 months</time_frame>
    <description>Related to the drug of inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of discontinuation due to lack of efficacy</measure>
    <time_frame>18 months</time_frame>
    <description>Related to the drug of inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>Time trade-off question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose adjustments</measure>
    <time_frame>18 months</time_frame>
    <description>Related to the drug of inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attitudes towards and knowledge of pharmacogenomics</measure>
    <time_frame>18 months</time_frame>
    <description>Composite outcome: a list of seven questions regarding pharmacogenomics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8100</enrollment>
  <condition>Adverse Drug Reaction</condition>
  <arm_group>
    <arm_group_label>Pharmacogenomic testing arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a &quot;Safety-Code card&quot; containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock &quot;Safety-Code card&quot;, which does not contain personal pharmacogenomics results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenomic testing</intervention_name>
    <description>The pharmacogenomic panel to be used incorporates 50 genetic variants for the following 13 &quot;pharamacogenes&quot;: CYP1A2 (cytochrome P450), CYP2B6, CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex).</description>
    <arm_group_label>Pharmacogenomic testing arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be ‚â• 18 years old

          -  Subject must receive a first prescription (meaning no known prescription for this drug
             in the preceding 12 months) for one or more of 42 drugs, for which a Dutch
             Pharmacogenomic Working Group guideline is available, which is prescribed to them in
             routine care

          -  Subject is able and willing to take part and be followed-up for at least 12 weeks

          -  Subject is able to donate blood or saliva

          -  Subject has signed informed consent

          -  The study limit of enrolment (200 per arm, per 18-month block) for that drug has not
             been reached

        Exclusion Criteria:

          -  Subject has previous (direct-to-consumer, or clinical) genetic testing for a gene
             important to the drug of inclusion

          -  Subject is pregnant or lactating

          -  Subject has a life expectancy estimated to be less than three months by treating
             clinical team

          -  Duration of the drug of inclusion total treatment length is planned to be less than
             seven consecutive days. A drug whose route of administration changes during the first
             seven days (e.g. intravenous to oral flucloxacillin) but whose total treatment
             duration is seven days or longer, is still eligible.

          -  For inpatients: hospital admission is expected to be less than 72 hours

          -  Subject is unable to consent to the study

          -  Subject is unwilling to take part

          -  Subject has no fixed address

          -  Subject has no current general practitioner

          -  Subject is, in the opinion of the Investigator, not suitable to participate in the
             study

          -  Subject has existing impaired hepatic or renal function for which a lower dose or
             alternate drug selection are already part of current routine care. This would not
             apply to any drugs specifically given to manage liver/renal
             impairment/transplantation.

          -  Subject has an estimated glomerular filtration rate (MDRD) of less than 15 ml/min per
             1,73m2 in a subject with a functioning graft

          -  Subject has advanced liver failure (stage Child-Pugh C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesse J. Swen, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Munir Pirmohamed, MB ChB(Hons) PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gere Sunder-Plassmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Toffoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro di Riferimento Oncologico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Luc√≠a D√°vila Fajardo, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andaluz Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George P. Patrinos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vita Dolzan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathelijne H van der Wouden, PharmD</last_name>
    <phone>+31 (0)70 5265879</phone>
    <email>c.h.van_der_wouden@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gere Sunder-Plassmann, MD</last_name>
      <email>gere.sunder-plassmann@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gere Sunder-Plassmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George P. Patrinos, PhD</last_name>
      <email>gpatrinos@upatras.gr</email>
    </contact>
    <investigator>
      <last_name>George P. Patrinos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Cecchin, PharmD PhD</last_name>
      <email>ececchin@cro.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Toffoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathelijne van der Wouden, PharmD</last_name>
      <email>c.h.van_der_wouden@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jesse J. Swen, PharmD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vita Dolzan, MD PhD</last_name>
      <email>vita.dolzan@mf.uni-lj.si</email>
    </contact>
    <investigator>
      <last_name>Vita Dolzan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servicio Andaluz de Salud</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina L. D√°vila Fajardo, PharmD PhD</last_name>
      <email>cldf28@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina L. D√°vila Fajardo, PharmD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Turner, MD</last_name>
      <email>Richard.Turner@liverpool.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Munir Pirmohamed, MB ChB(Hons) PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://upgx.eu/</url>
    <description>Ubiquitous Pharmacogenomics (U-PGx) Consortium Official Website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.J.Swen</investigator_full_name>
    <investigator_title>Associate Professor of Pharmacogenetics, Section Chair Laboratory, Department of Clinical Pharmacy and Toxicology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

